Multidrug Resistance Modulation and Apoptosis Induction of Cancer Cells by Terpenic Compounds Isolated from Euphorbia Species
Background: One of the most promising strategies to overcome multidrug resistance (MDR) is to use compounds that can modulate P-glycoprotein and restore the cytotoxicity of anticancer drugs. Furthermore, the search for compounds that regulate and overcome apoptosis deficiency of cancer cells is also...
Saved in:
Published in: | Anticancer research Vol. 29; no. 11; pp. 4467 - 4472 |
---|---|
Main Authors: | , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Greece
International Institute of Anticancer Research
01-11-2009
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Background: One of the most promising strategies to overcome multidrug resistance (MDR) is to use compounds that can modulate
P-glycoprotein and restore the cytotoxicity of anticancer drugs. Furthermore, the search for compounds that regulate and overcome
apoptosis deficiency of cancer cells is also of great therapeutic importance. Materials and Methods: Seven known pentacyclic
triterpenes and one steroid were isolated from Euphorbia lagascae methanolic extracts and identified by physical and spectroscopic
methods. These compounds, together with eleven terpenoids previously isolated from Euphorbia lagascae and E. tuckeyana were
tested for their MDR-reversing and/or apoptosis induction activities by flow cytometry on L5178 human MDR1 gene-transfected
mouse lymphoma cells. Results: Four taraxastane-type triterpenes: 21α-hydroxytaraxasterol, 21α-hydroxytaraxasterol acetate,
3β,30-dihydroxy-20(21)-taraxastene and 3β-hydroxy-20-taraxasten-30-al, and two steroids: stigmastane-3,6-dione and ergosterol
peroxide exhibited a significant MDR-Pgp modulation activity. Some aspects of structureâactivity relationships are discussed.
Regarding apoptosis induction, the most significant results were obtained for the polycyclic diterpenes ent-16α,17-dihydroxykauran-3-one
and ent-16α,17-dihydroxyatisan-3-one. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0250-7005 1791-7530 |